Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study

• Published in: Neurology Vol. 63; no. 10; p. 1788
• Main Authors: Panitch, Hillel, Miller, Aaron, Paty, Donald, Weinshenker, Brian
• Format: Journal Article
• Language: English
• Published: United States 23.11.2004
• Subjects: Brain - pathology; Contrast Media; Depression; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Gadolinium; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - adverse effects; Immunologic Factors - immunology; Immunologic Factors - therapeutic use; Injections, Subcutaneous; Interferon beta-1b; Interferon-beta - administration & dosage; Interferon-beta - adverse effects; Interferon-beta - immunology; Interferon-beta - therapeutic use; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive - drug therapy; Multiple Sclerosis, Chronic Progressive - pathology; Multiple Sclerosis, Chronic Progressive - psychology; Neutralization Tests; Outcome Assessment (Health Care); Quality of Life; Severity of Illness Index

To evaluate the efficacy and safety of interferon beta-1b (IFNbeta-1b) in subjects with secondary progressive multiple sclerosis (SPMS). This 3-year, multicenter, double-blind, placebo-controlled, randomized trial of IFNbeta-1b included 939 subjects from the United States and Canada with SPMS and Ex...